Genus Oncology was formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the Mucin 1 (MUC1) oncoprotein. The incidence of overexpressed MUC1 in a wide array of carcinomas and hematologic malignancies has been known by researchers for many years. Until now, no viable approach existed to